Compound Library Consortium

By Muralikrishna Valluri, Ph.D. & Douglas B. Kitchen, Ph.D., Curia

Creating high-quality, innovative small molecule leads remains a persistent challenge in drug discovery. Despite escalating costs, the rate of drug discovery has stagnated for over 60 years, making the improvement of research and development productivity a significant obstacle for the pharmaceutical sector.

Addressing these challenges requires innovative methods. High-throughput screening (HTS) is a fundamental component of drug discovery; however, the success of a drug discovery campaign often hinges on the availability of an innovative, relevant, and high-quality compound collection for screening. The vast and sparsely populated chemical space necessitates substantial investment to generate and maintain a competitive compound collection.

Leveraging diverse experience and industrial expertise in synthetic and medicinal chemistry, Curia addresses this challenge through the Compound Library Consortium (CLC), offering a novel approach to enhancing the effectiveness and efficiency of drug discovery efforts. This white paper explores how Curia’s CLC can significantly improve the chances of identifying promising drug candidates, ultimately accelerating the path from discovery to development.